Director Share Purchase

RNS Number : 9613I

Oxford Biomedica PLC

21 April 2022

Directors Dealings / Market Share Purchase

Oxford, UK - 21 April 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that that the Company's Chair & Interim Chief Executive Officer has increased his shareholding in the Company through the purchase of shares.

Dr. Roch Doliveux, Chair & Interim Chief Executive Officer of the Group, has purchased 58,219 ordinary shares of 50p each ("Ordinary Shares") in the Company on 21 April 2022 on the London Stock Exchange at a price of 589.3p. Following this purchase Dr. Roch Doilveux holds 273,678 shares representing 0.285% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.	Details of the person discharging material responsibilities/person closely associated
a.	Name	Roch Doliveux
2.	Reason for the notification
a.	Position/status	Chair & Interim CEO
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£5.89	58,219

e.	Aggregated information · Aggregated volume · Price · Aggregated total	58,219 £5.8933 £343,102.03
f.	Date of the transaction	2022-04-21
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:

Oxford Biomedica plc:

Natalie Walter, Company Secretary

Tel: +44 (0)1865 783 000

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFVESAILFIF